Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

HuGENet™: Fact sheets
chromosome


CCR5 receptor gene and HIV infection
PUBLISHED: April 2002
AUTHORS: Antonio Guilherme Fonseca Pacheco, (University of Pittsburgh)

 Download print version Link here to download free  Adobe Reader (14KB)

line

squares CCR5 GENE

The gene for CCR5 is located on chromosome 3 in the p21.3-p24  region. CCR5 is a chemokine receptor present in different cells, especially in macrophages, monocytes, and T cells, where it acts as a co-receptor for HIV-1 in these cells. Chemokines and their receptors are believed to be involved in the inflammatory response, mediating  leukocyte movement and activation.


squares PREVALENCE OF GENE VARIANTS

At least 23 alleles have been described for the coding region of this gene, and most of them are very rare. The most common and most studied is the 32 allele, a 32 base pair (bp) deletion that confers almost absolute protection from infection with macrophage tropic (M-tropic) viruses in homozygous individuals and provides an average 2 to 3 year delay in the progression to AIDS in those heterozygous for the deletion. The allele's prevalence varies by ethnicity, being as high as 10%-15% in Caucasians, ~2% in African Americans, and virtually absent in native Africans and East Asians (3,6). Several single nucleotide polymorphisms (SNPs) were described in the promoter region of CCR5, accounting for six different important haplotypes. Many studies showed that the 64I allele of another chemokine receptor coding gene, CCR2, is in very strong linkage disequilibrium with one allele of the promoter region of CCR5 (1), invariably in combination with CCR5+ (now named haplotype F*2). These findings led to the modern classification of 9 haplotypes for CCR5 (A, B, C, D, E, F*1, F*2, G*1, and G*2; the latter corresponding to the CCR2delta32 allele) that actually encompass its open reading frame, the promoter region, and the CCR2 gene (3,8). Gonzales et al. have recently published world-wide distributions of these haplotypes, showing great variation in their frequencies (3).


squares DISEASE BURDEN

Ninety percent of the infections caused by HIV 1 involve the so-called M-tropic (or R5-tropic) strains. In addition to the CD4 receptor present in macrophages, monocytes, and T cells, these strains also need the presence of a CCR5 receptor on the cell surface to infect. The 32 bp deletion causes the resultant protein to be truncated and inactive, and individuals homozygous for the delta 32 allele present undetectable concentrations of the receptor, while heterozygous individuals have 20%-30% of the wild type concentrations (5,6). The result is that homozygous individuals exposed to M-tropic strains are protected from infection, while infected heterozygous individuals present a slower progression to both AIDS and death. In a cohort of 2,996 people, Marmor et al. showed only one seroconversion among 39 CCR5delta32/ delta 32 participants, but this was a T-tropic strain that uses the CXCR4 receptor instead of the CCR5 receptor. In the same study, the risk ratio (RR) for seroconversion was 0.30 (95% Confidence Interval: 0.08-0.96) in the CCR5delta32/+ group compared with the CCR5+/+ group when controlled for unprotected receptive anal sex (4). In another study that combined five different cohorts totaling 3,003 patients, Smith et al. showed that seropositive heterozygous individuals had a prolonged survival time to AIDS (Relative Hazard (RH) = 0.68, p = 0.002) and to death (RH = 0.67, p = 0.02) (7).

In a recent study by Tang et al., some features of the nine CCR5 haplotypes were studied, and the haplotype G * 2, especially the genotype A/G * 2, was more frequent in individuals highly exposed to HIV and persistently seronegative (OR = 0.54, 95% CI: 0.32-0.89) (8). Viral load during the first 42 months of infection was lower in G*2 carriers, especially among those with genotypes A/G * 2 and F *2/G*2). Progression to AIDS was also delayed for G * 2 carriers.


squares
INTERACTIONS

Several factors interact in HIV 1 transmission since the infection depends on variables related to susceptibility, transmissibility, and host response to infection. Several other genes may play a role in the susceptibility of the cells to HIV infection. The role of gene expression of CCR5 chemokine ligands in HIV infection has been the subject of intense research, since the suppression of these ligands, secondary to CD8 + cell depletion in HIV-positive patients, has been demonstrated to lead, at least in part, to accelerated viral replication. Although there is strong evidence of potent inhibition of HIV replication in vitro, studying RANTES, MIP-1alpha and MIP-1ß expressions in HIV positive cohorts has shown conflicting results (2).


squares
LABORATORY TESTS

Several different methods have been used for CCR5 genotyping, but the most common methods are DNA-PCR, followed by restriction fragment length polymorphism (RFLP) or sequencing.


squares
POPULATION TESTING

To date, no recommendation on population testing has been issued. Since the major factor in HIV infection is exposure to the virus, protective measures against the exposure continue to be recommended as public health policy.


squares
REFERENCES

  1. Carrington, M., et al., Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet, 1999. 8(10): p. 1939-45.
  2. Gallo, R.C., A. Garzino-Demo, and A.L. DeVico, HIV infection and pathogenesis: what about chemokines? J Clin Immunol, 1999. 19(5): p. 293-9.
  3. Gonzalez, E., et al., Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5199-204.
  4. Marmor, M., et al., Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr, 2001. 27(5): p. 472-81.
  5. McNicholl, J.M., et al., Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. Emerg Infect Dis, 1997. 3(3): p. 261-71.
  6. O'Brien, S.J. and J.P. Moore, The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev, 2000. 177: p. 99-111.
  7. Smith, M.W., et al., Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science, 1997. 277(5328): p. 959-65.
  8. Tang, J., et al., Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol. 2002 6(2):662-72.

squares WEBSITES

  1. UNAIDS This reference links to a non-governmental website
  2. JAMA HIV/AIDS Resource Center This reference links to a non-governmental website
  3. Johns Hopkins AIDS Service This reference links to a non-governmental website
  4. Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention
This reference links to a non-governmental website
 Provides link to non-governmental sites and does not necessarily represent the views of the Centers  for Disease Control and Prevention.
Page last reviewed: April 1, 2002 (archived document)
Page last updated: November 2, 2007
Content Source: National Office of Public Health Genomics